Skip to content
Asembia AXS26

Asembia AXS26: Highlights from Asembia

Author: 1 minute read

From Downloads to Decisions: How AXS26 Day 1 Redefined Success in Patient Affordability 

Las Vegas has a way of amplifying energy, and Day 1 of Asembia Specialty Pharmacy Summit at Wynn & Encore Las Vegas didn’t disappoint. The floors were buzzing—not with small talk, but with a conversation the industry has been circling for years: are affordability programs actually working, or are we just measuring the wrong things? 

That tension set the tone for everything.

Asembia collage

On the ground, the Product Theater drew a packed room and an even sharper discussion. The opening session, “The Download Trap: Why Affordability Programs Need New Success Metrics,” cut straight to the point. Moderated by Vijay Adapala, Chief Business Development Officer, Doceree, alongside Nicolas Kernick, Head of Growth & Operations, Develop Health, Kevin Boesen, Chief Commercial Officer, Outcomes Health, and Jeff Davis, VP – Sales, Life Sciences, NimbleRx, the panel made one thing clear—downloads and registrations are vanity metrics. What matters is whether patients actually fill prescriptions and stay on therapy.

The fireside chat that followed, moderated by Andrew Matthews, SVP – Sales, Patient Affordability Solutions, Doceree, with Daniel Keene, VP – Head of US Patient Services, Alnylam, pushed the conversation further into practical territory. How do you build affordability strategies that hold up inside complex organizations while still moving the needle for real patients? No easy answers—but the right questions are finally being asked out loud.

Closing the session, Thomas Shea, Chief Revenue Officer, Doceree, brought it back to execution: simplify co-pay discovery, reduce friction at activation, and get patients to therapy faster. It sounds obvious—and yet it remains one of the industry’s most persistent gaps.

What stood out wasn’t any single session, but the shift in language. “Accountability” came up more than once. Success is no longer about engagement rates; it’s about whether a patient started—and stayed—on treatment.

If Day 1 is any signal, AXS26 isn’t just revisiting old problems—it’s demanding better answers. And as the conversation deepens over the coming days, the focus will only sharpen: turning intent into action, and access into measurable impact.

Get ready for Day 2—where these conversations move from perspective to progression.

More from the floor tomorrow.

To explore more, visit us at: Doceree co-pay